Published in Front Immunol on July 22, 2014
The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz) (2015) 0.81
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol (2016) 0.79
Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. Oncotarget (2016) 0.78
The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol (2016) 0.77
Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci (2016) 0.76
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. Br J Cancer (2016) 0.75
TLR-exosomes exhibit distinct kinetics and effector function. Sci Rep (2017) 0.75
Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes Cancer (2015) 0.75
Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply. Int J Mol Sci (2017) 0.75
Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells. Oncol Lett (2017) 0.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Cancer of the ovary. N Engl J Med (2004) 11.21
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
TLR signaling pathways. Semin Immunol (2004) 9.08
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev (2001) 5.09
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol (2011) 4.00
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene (2008) 2.31
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res (2001) 2.29
TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18
Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03
Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene (2008) 1.93
Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol (2008) 1.89
Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol (2007) 1.76
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol (2007) 1.65
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol (2008) 1.50
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Toll-like receptors: networking for success. Eur J Immunol (2003) 1.45
Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 1.41
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2011) 1.25
Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer (2006) 1.23
Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother (2008) 1.23
Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother (2009) 1.21
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine (2005) 1.04
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle (2010) 1.02
Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol (2006) 1.02
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Tumor growth or regression: powered by inflammation. J Leukoc Biol (2006) 0.96
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother (2010) 0.93
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther (2009) 0.91
Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol (2012) 0.91
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol (2013) 0.84
Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies. Front Oncol (2014) 0.84
TLR4 activates NF-κB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun (2011) 0.83
TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol (2014) 0.81
Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies. Front Oncol (2014) 0.84